26 results match your criteria: "Central Laboratory and Vaccination Centre[Affiliation]"
Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature.
Gynecol Oncol
September 2008
Central Laboratory and Vaccination Centre, Stiftung Juliusspital Würzburg, Juliuspromenade 19, 97070 Würzburg, Germany.
An AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine has demonstrated excellent efficacy for up to 6.4 years in preventing related persistent infections and cervical precancerous lesions in both Phase II and Phase III clinical trials. The immune responses induced by HPV vaccination are different to those after natural infection.
View Article and Find Full Text PDF